DLL4 and head and neck squamous cell carcinoma: A recent study demonstrated that GD16-PTX-NP, a nanotherapy drug delivery system consisting of nanoparticles carrying paclitaxel conjugated with GD16 peptide, targeted Dll4 in human head and neck squamous cell carcinoma (HNSCC) FaDu xenograft mice.